The European response to the WHO call to eliminate cervical cancer as a public health problem.
Identifieur interne : 000472 ( Main/Exploration ); précédent : 000471; suivant : 000473The European response to the WHO call to eliminate cervical cancer as a public health problem.
Auteurs : Marc Arbyn [Belgique] ; Murat Gultekin [Turquie] ; Philippe Morice [France] ; Pekka Nieminen [Finlande] ; Maggie Cruickshank [Royaume-Uni] ; Philip Poortmans [Belgique] ; Daniel Kelly [Royaume-Uni] ; Mario Poljak [Slovénie] ; Christine Bergeron [France] ; David Ritchie [Belgique] ; Dietmar Schmidt [Allemagne] ; Maria Kyrgiou [Royaume-Uni] ; Ann Van Den Bruel [Belgique] ; Laia Bruni [Espagne] ; Partha Basu [France] ; Freddie Bray [France] ; Elisabete Weiderpass [France]Source :
- International journal of cancer [ 1097-0215 ] ; 2020.
Abstract
The age-standardised incidence of cervical cancer in Europe varies widely by country (between 3 and 25/100000 women-years) in 2018. Human papillomavirus (HPV) vaccine coverage is low in countries with the highest incidence and screening performance is heterogeneous among European countries. A broad group of delegates of scientific professional societies and cancer organisations endorse the principles of the WHO call to eliminate cervical cancer as a public health problem, also in Europe. All European nations should, by 2030, reach at least 90% HPV vaccine coverage among girls by the age of 15 years and also boys, if cost-effective; they should introduce organised population-based HPV-based screening and achieve 70% of screening coverage in the target age group, providing also HPV testing on self-samples for nonscreened or underscreened women; and to manage 90% of screen-positive women. To guide member states, a group of scientific professional societies and cancer organisations engage to assist in the rollout of a series of concerted evidence-based actions. European health authorities are requested to mandate a group of experts to develop the third edition of European Guidelines for Quality Assurance of Cervical Cancer prevention based on integrated HPV vaccination and screening and to monitor the progress towards the elimination goal. The occurrence of the COVID-19 pandemic, having interrupted prevention activities temporarily, should not deviate stakeholders from this ambition. In the immediate postepidemic phase, health professionals should focus on high-risk women and adhere to cost-effective policies including self-sampling.
DOI: 10.1002/ijc.33189
PubMed: 32638362
Affiliations:
- Allemagne, Belgique, Espagne, Finlande, France, Royaume-Uni, Slovénie, Turquie
- Angleterre, Auvergne-Rhône-Alpes, Catalogne, Grand Londres, Rhône-Alpes, Région de Bruxelles-Capitale
- Barcelone, Bruxelles, Londres, Lyon, Villejuif
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The European response to the WHO call to eliminate cervical cancer as a public health problem.</title><author><name sortKey="Arbyn, Marc" sort="Arbyn, Marc" uniqKey="Arbyn M" first="Marc" last="Arbyn">Marc Arbyn</name><affiliation wicri:level="3"><nlm:affiliation>Coordinator Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Coordinator Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Gultekin, Murat" sort="Gultekin, Murat" uniqKey="Gultekin M" first="Murat" last="Gultekin">Murat Gultekin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University Faculty of Medicine, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Morice, Philippe" sort="Morice, Philippe" uniqKey="Morice P" first="Philippe" last="Morice">Philippe Morice</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gynecologic Surgery, Gustave Roussy Institute, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Gynecologic Surgery, Gustave Roussy Institute, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation></author><author><name sortKey="Nieminen, Pekka" sort="Nieminen, Pekka" uniqKey="Nieminen P" first="Pekka" last="Nieminen">Pekka Nieminen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynaecology, University of Helsinki and University Hospital of Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Obstetrics and Gynaecology, University of Helsinki and University Hospital of Helsinki</wicri:regionArea><wicri:noRegion>University of Helsinki and University Hospital of Helsinki</wicri:noRegion></affiliation></author><author><name sortKey="Cruickshank, Maggie" sort="Cruickshank, Maggie" uniqKey="Cruickshank M" first="Maggie" last="Cruickshank">Maggie Cruickshank</name><affiliation wicri:level="1"><nlm:affiliation>Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen</wicri:regionArea><wicri:noRegion>Aberdeen</wicri:noRegion></affiliation></author><author><name sortKey="Poortmans, Philip" sort="Poortmans, Philip" uniqKey="Poortmans P" first="Philip" last="Poortmans">Philip Poortmans</name><affiliation wicri:level="3"><nlm:affiliation>European Cancer Organisation, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>European Cancer Organisation, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Kelly, Daniel" sort="Kelly, Daniel" uniqKey="Kelly D" first="Daniel" last="Kelly">Daniel Kelly</name><affiliation wicri:level="1"><nlm:affiliation>School of Healthcare Sciences, Cardiff University, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Healthcare Sciences, Cardiff University</wicri:regionArea><wicri:noRegion>Cardiff University</wicri:noRegion></affiliation></author><author><name sortKey="Poljak, Mario" sort="Poljak, Mario" uniqKey="Poljak M" first="Mario" last="Poljak">Mario Poljak</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</nlm:affiliation><country xml:lang="fr">Slovénie</country><wicri:regionArea>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana</wicri:regionArea><wicri:noRegion>Ljubljana</wicri:noRegion></affiliation></author><author><name sortKey="Bergeron, Christine" sort="Bergeron, Christine" uniqKey="Bergeron C" first="Christine" last="Bergeron">Christine Bergeron</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Cerba, Cergy Pontoise, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Cerba, Cergy Pontoise</wicri:regionArea><wicri:noRegion>Cergy Pontoise</wicri:noRegion><wicri:noRegion>Cergy Pontoise</wicri:noRegion></affiliation></author><author><name sortKey="Ritchie, David" sort="Ritchie, David" uniqKey="Ritchie D" first="David" last="Ritchie">David Ritchie</name><affiliation wicri:level="3"><nlm:affiliation>Association of European Cancer Leagues, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Association of European Cancer Leagues, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Schmidt, Dietmar" sort="Schmidt, Dietmar" uniqKey="Schmidt D" first="Dietmar" last="Schmidt">Dietmar Schmidt</name><affiliation wicri:level="1"><nlm:affiliation>MVZ of Pathology, Cytology and Molecular Diagnostics, Trier, University of Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>MVZ of Pathology, Cytology and Molecular Diagnostics, Trier, University of Kiel</wicri:regionArea><wicri:noRegion>University of Kiel</wicri:noRegion><wicri:noRegion>University of Kiel</wicri:noRegion><wicri:noRegion>University of Kiel</wicri:noRegion></affiliation></author><author><name sortKey="Kyrgiou, Maria" sort="Kyrgiou, Maria" uniqKey="Kyrgiou M" first="Maria" last="Kyrgiou">Maria Kyrgiou</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gut, Metabolism and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Gut, Metabolism and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London</wicri:regionArea><wicri:noRegion>Imperial College London</wicri:noRegion></affiliation><affiliation wicri:level="3"><nlm:affiliation>West London Gynaecological Cancer Centre, Imperial College Healthcare NHS Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>West London Gynaecological Cancer Centre, Imperial College Healthcare NHS Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Van Den Bruel, Ann" sort="Van Den Bruel, Ann" uniqKey="Van Den Bruel A" first="Ann" last="Van Den Bruel">Ann Van Den Bruel</name><affiliation wicri:level="1"><nlm:affiliation>Academic Centre for General Practice, University of Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Academic Centre for General Practice, University of Leuven</wicri:regionArea><wicri:noRegion>University of Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Bruni, Laia" sort="Bruni, Laia" uniqKey="Bruni L" first="Laia" last="Bruni">Laia Bruni</name><affiliation wicri:level="3"><nlm:affiliation>Cancer Epidemiology Research Program, Catalan Institute of Oncology - IDIBELL, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Cancer Epidemiology Research Program, Catalan Institute of Oncology - IDIBELL, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Basu, Partha" sort="Basu, Partha" uniqKey="Basu P" first="Partha" last="Basu">Partha Basu</name><affiliation wicri:level="3"><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Agency for Research on Cancer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bray, Freddie" sort="Bray, Freddie" uniqKey="Bray F" first="Freddie" last="Bray">Freddie Bray</name><affiliation wicri:level="3"><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Agency for Research on Cancer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Weiderpass, Elisabete" sort="Weiderpass, Elisabete" uniqKey="Weiderpass E" first="Elisabete" last="Weiderpass">Elisabete Weiderpass</name><affiliation wicri:level="3"><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Agency for Research on Cancer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32638362</idno><idno type="pmid">32638362</idno><idno type="doi">10.1002/ijc.33189</idno><idno type="wicri:Area/Main/Corpus">000A63</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A63</idno><idno type="wicri:Area/Main/Curation">000A63</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A63</idno><idno type="wicri:Area/Main/Exploration">000A63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The European response to the WHO call to eliminate cervical cancer as a public health problem.</title><author><name sortKey="Arbyn, Marc" sort="Arbyn, Marc" uniqKey="Arbyn M" first="Marc" last="Arbyn">Marc Arbyn</name><affiliation wicri:level="3"><nlm:affiliation>Coordinator Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Coordinator Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Gultekin, Murat" sort="Gultekin, Murat" uniqKey="Gultekin M" first="Murat" last="Gultekin">Murat Gultekin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University Faculty of Medicine, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Morice, Philippe" sort="Morice, Philippe" uniqKey="Morice P" first="Philippe" last="Morice">Philippe Morice</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gynecologic Surgery, Gustave Roussy Institute, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Gynecologic Surgery, Gustave Roussy Institute, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation></author><author><name sortKey="Nieminen, Pekka" sort="Nieminen, Pekka" uniqKey="Nieminen P" first="Pekka" last="Nieminen">Pekka Nieminen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynaecology, University of Helsinki and University Hospital of Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Obstetrics and Gynaecology, University of Helsinki and University Hospital of Helsinki</wicri:regionArea><wicri:noRegion>University of Helsinki and University Hospital of Helsinki</wicri:noRegion></affiliation></author><author><name sortKey="Cruickshank, Maggie" sort="Cruickshank, Maggie" uniqKey="Cruickshank M" first="Maggie" last="Cruickshank">Maggie Cruickshank</name><affiliation wicri:level="1"><nlm:affiliation>Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen</wicri:regionArea><wicri:noRegion>Aberdeen</wicri:noRegion></affiliation></author><author><name sortKey="Poortmans, Philip" sort="Poortmans, Philip" uniqKey="Poortmans P" first="Philip" last="Poortmans">Philip Poortmans</name><affiliation wicri:level="3"><nlm:affiliation>European Cancer Organisation, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>European Cancer Organisation, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Kelly, Daniel" sort="Kelly, Daniel" uniqKey="Kelly D" first="Daniel" last="Kelly">Daniel Kelly</name><affiliation wicri:level="1"><nlm:affiliation>School of Healthcare Sciences, Cardiff University, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Healthcare Sciences, Cardiff University</wicri:regionArea><wicri:noRegion>Cardiff University</wicri:noRegion></affiliation></author><author><name sortKey="Poljak, Mario" sort="Poljak, Mario" uniqKey="Poljak M" first="Mario" last="Poljak">Mario Poljak</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</nlm:affiliation><country xml:lang="fr">Slovénie</country><wicri:regionArea>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana</wicri:regionArea><wicri:noRegion>Ljubljana</wicri:noRegion></affiliation></author><author><name sortKey="Bergeron, Christine" sort="Bergeron, Christine" uniqKey="Bergeron C" first="Christine" last="Bergeron">Christine Bergeron</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Cerba, Cergy Pontoise, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Cerba, Cergy Pontoise</wicri:regionArea><wicri:noRegion>Cergy Pontoise</wicri:noRegion><wicri:noRegion>Cergy Pontoise</wicri:noRegion></affiliation></author><author><name sortKey="Ritchie, David" sort="Ritchie, David" uniqKey="Ritchie D" first="David" last="Ritchie">David Ritchie</name><affiliation wicri:level="3"><nlm:affiliation>Association of European Cancer Leagues, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Association of European Cancer Leagues, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Schmidt, Dietmar" sort="Schmidt, Dietmar" uniqKey="Schmidt D" first="Dietmar" last="Schmidt">Dietmar Schmidt</name><affiliation wicri:level="1"><nlm:affiliation>MVZ of Pathology, Cytology and Molecular Diagnostics, Trier, University of Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>MVZ of Pathology, Cytology and Molecular Diagnostics, Trier, University of Kiel</wicri:regionArea><wicri:noRegion>University of Kiel</wicri:noRegion><wicri:noRegion>University of Kiel</wicri:noRegion><wicri:noRegion>University of Kiel</wicri:noRegion></affiliation></author><author><name sortKey="Kyrgiou, Maria" sort="Kyrgiou, Maria" uniqKey="Kyrgiou M" first="Maria" last="Kyrgiou">Maria Kyrgiou</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gut, Metabolism and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Gut, Metabolism and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London</wicri:regionArea><wicri:noRegion>Imperial College London</wicri:noRegion></affiliation><affiliation wicri:level="3"><nlm:affiliation>West London Gynaecological Cancer Centre, Imperial College Healthcare NHS Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>West London Gynaecological Cancer Centre, Imperial College Healthcare NHS Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Van Den Bruel, Ann" sort="Van Den Bruel, Ann" uniqKey="Van Den Bruel A" first="Ann" last="Van Den Bruel">Ann Van Den Bruel</name><affiliation wicri:level="1"><nlm:affiliation>Academic Centre for General Practice, University of Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Academic Centre for General Practice, University of Leuven</wicri:regionArea><wicri:noRegion>University of Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Bruni, Laia" sort="Bruni, Laia" uniqKey="Bruni L" first="Laia" last="Bruni">Laia Bruni</name><affiliation wicri:level="3"><nlm:affiliation>Cancer Epidemiology Research Program, Catalan Institute of Oncology - IDIBELL, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Cancer Epidemiology Research Program, Catalan Institute of Oncology - IDIBELL, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Basu, Partha" sort="Basu, Partha" uniqKey="Basu P" first="Partha" last="Basu">Partha Basu</name><affiliation wicri:level="3"><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Agency for Research on Cancer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bray, Freddie" sort="Bray, Freddie" uniqKey="Bray F" first="Freddie" last="Bray">Freddie Bray</name><affiliation wicri:level="3"><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Agency for Research on Cancer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Weiderpass, Elisabete" sort="Weiderpass, Elisabete" uniqKey="Weiderpass E" first="Elisabete" last="Weiderpass">Elisabete Weiderpass</name><affiliation wicri:level="3"><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Agency for Research on Cancer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></analytic><series><title level="j">International journal of cancer</title><idno type="eISSN">1097-0215</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The age-standardised incidence of cervical cancer in Europe varies widely by country (between 3 and 25/100000 women-years) in 2018. Human papillomavirus (HPV) vaccine coverage is low in countries with the highest incidence and screening performance is heterogeneous among European countries. A broad group of delegates of scientific professional societies and cancer organisations endorse the principles of the WHO call to eliminate cervical cancer as a public health problem, also in Europe. All European nations should, by 2030, reach at least 90% HPV vaccine coverage among girls by the age of 15 years and also boys, if cost-effective; they should introduce organised population-based HPV-based screening and achieve 70% of screening coverage in the target age group, providing also HPV testing on self-samples for nonscreened or underscreened women; and to manage 90% of screen-positive women. To guide member states, a group of scientific professional societies and cancer organisations engage to assist in the rollout of a series of concerted evidence-based actions. European health authorities are requested to mandate a group of experts to develop the third edition of European Guidelines for Quality Assurance of Cervical Cancer prevention based on integrated HPV vaccination and screening and to monitor the progress towards the elimination goal. The occurrence of the COVID-19 pandemic, having interrupted prevention activities temporarily, should not deviate stakeholders from this ambition. In the immediate postepidemic phase, health professionals should focus on high-risk women and adhere to cost-effective policies including self-sampling.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32638362</PMID><DateRevised><Year>2020</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0215</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>International journal of cancer</Title><ISOAbbreviation>Int. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>The European response to the WHO call to eliminate cervical cancer as a public health problem.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.33189</ELocationID><Abstract><AbstractText>The age-standardised incidence of cervical cancer in Europe varies widely by country (between 3 and 25/100000 women-years) in 2018. Human papillomavirus (HPV) vaccine coverage is low in countries with the highest incidence and screening performance is heterogeneous among European countries. A broad group of delegates of scientific professional societies and cancer organisations endorse the principles of the WHO call to eliminate cervical cancer as a public health problem, also in Europe. All European nations should, by 2030, reach at least 90% HPV vaccine coverage among girls by the age of 15 years and also boys, if cost-effective; they should introduce organised population-based HPV-based screening and achieve 70% of screening coverage in the target age group, providing also HPV testing on self-samples for nonscreened or underscreened women; and to manage 90% of screen-positive women. To guide member states, a group of scientific professional societies and cancer organisations engage to assist in the rollout of a series of concerted evidence-based actions. European health authorities are requested to mandate a group of experts to develop the third edition of European Guidelines for Quality Assurance of Cervical Cancer prevention based on integrated HPV vaccination and screening and to monitor the progress towards the elimination goal. The occurrence of the COVID-19 pandemic, having interrupted prevention activities temporarily, should not deviate stakeholders from this ambition. In the immediate postepidemic phase, health professionals should focus on high-risk women and adhere to cost-effective policies including self-sampling.</AbstractText><CopyrightInformation>© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arbyn</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7807-5908</Identifier><AffiliationInfo><Affiliation>Coordinator Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gultekin</LastName><ForeName>Murat</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-4221-4459</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morice</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gynecologic Surgery, Gustave Roussy Institute, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieminen</LastName><ForeName>Pekka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, University of Helsinki and University Hospital of Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruickshank</LastName><ForeName>Maggie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poortmans</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7400-2293</Identifier><AffiliationInfo><Affiliation>European Cancer Organisation, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-1847-0655</Identifier><AffiliationInfo><Affiliation>School of Healthcare Sciences, Cardiff University, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poljak</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3216-7564</Identifier><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergeron</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire Cerba, Cergy Pontoise, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Association of European Cancer Leagues, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>MVZ of Pathology, Cytology and Molecular Diagnostics, Trier, University of Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyrgiou</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7165-0735</Identifier><AffiliationInfo><Affiliation>Department of Gut, Metabolism and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>West London Gynaecological Cancer Centre, Imperial College Healthcare NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Bruel</LastName><ForeName>Ann</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9012-2009</Identifier><AffiliationInfo><Affiliation>Academic Centre for General Practice, University of Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruni</LastName><ForeName>Laia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Research Program, Catalan Institute of Oncology - IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basu</LastName><ForeName>Partha</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0124-4050</Identifier><AffiliationInfo><Affiliation>International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bray</LastName><ForeName>Freddie</ForeName><Initials>F</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3248-7787</Identifier><AffiliationInfo><Affiliation>International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiderpass</LastName><ForeName>Elisabete</ForeName><Initials>E</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-2237-0128</Identifier><AffiliationInfo><Affiliation>International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2019</GrantID><Agency>European Society of Gynaecologic Oncology</Agency><Country></Country></Grant><Grant><GrantID>847845</GrantID><Agency>Horizon 2020 Framework Programme</Agency><Country></Country></Grant><Grant><GrantID>IHUVAC</GrantID><Agency>Stichting Tegen Kanker</Agency><Country></Country></Grant><Grant><Agency>International Agency for Research on Cancer (IARC)</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Cancer</MedlineTA><NlmUniqueID>0042124</NlmUniqueID><ISSNLinking>0020-7136</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Europe</Keyword><Keyword MajorTopicYN="N">HPV vaccination</Keyword><Keyword MajorTopicYN="N">WHO</Keyword><Keyword MajorTopicYN="N">cervical cancer screening</Keyword><Keyword MajorTopicYN="N">elimination of cervical cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32638362</ArticleId><ArticleId IdType="doi">10.1002/ijc.33189</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191-e120.</Citation></Reference><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.</Citation></Reference><Reference><Citation>Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941-1953.</Citation></Reference><Reference><Citation>Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet. 1987;1:1247-1249.</Citation></Reference><Reference><Citation>Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014;111:965-969.</Citation></Reference><Reference><Citation>Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009;45:2640-2648.</Citation></Reference><Reference><Citation>European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening. Luxembourg: Office for Official Publications of the European Communities; 2008:291.</Citation></Reference><Reference><Citation>Dillner J, Sparen P, Andrae B, Strander B. Cervical cancer has increased in Sweden in women who had a normal cell sample. Lakartidningen. 2018;115:E9FD.</Citation></Reference><Reference><Citation>McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA. Disease burden of human papillomavirus infection in The Netherlands, 1989-2014: the gap between females and males is diminishing. Cancer Causes Control. 2017;28:203-214.</Citation></Reference><Reference><Citation>Castanon A, Sasieni P. Is the recent increase in cervical cancer in women aged 20-24years in England a cause for concern? Prev Med. 2018;107:21-28.</Citation></Reference><Reference><Citation>Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5(CD009069):1-241.</Citation></Reference><Reference><Citation>Xu L, Selk A, Garland SM, et al. Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. Expert Rev Vaccines. 2019;18:1157-1166.</Citation></Reference><Reference><Citation>Beachler DC, Kreimer AR, Schiffman M, et al. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J Natl Cancer Inst. 2015;108:djv302.</Citation></Reference><Reference><Citation>Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of Quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401-411.</Citation></Reference><Reference><Citation>Palefsky JM, Giuliano AR, Goldstone SE, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576-1585.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. 2020: 1-54. Stockholm.</Citation></Reference><Reference><Citation>Datta S, Pink J, Medley GF, et al. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK. BMC Infect Dis. 2019;19:552.</Citation></Reference><Reference><Citation>Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(5):F88-F99.</Citation></Reference><Reference><Citation>Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524-532.</Citation></Reference><Reference><Citation>Arbyn M, Verdoodt F, Snijders PJF, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15:172-183.</Citation></Reference><Reference><Citation>Arbyn M, Smith SB, Temin S, Sultana F, Castle PE, the Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823.</Citation></Reference><Reference><Citation>Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem. Geneva, Switzerland: WHO; 2019. https://www.who.int/docs/default-source/documents/cervical-cancer-elimination-draft-strategy.pdf</Citation></Reference><Reference><Citation>Arbyn M, Anttila A, Jordan J, et al. European guidelines for quality Assurance in Cervical Cancer Screening. Second edition-summary document. Ann Oncol. 2010;21:448-458.</Citation></Reference><Reference><Citation>O'Connor M, O'Leary E, Waller J, et al. Socio-economic variations in anticipated adverse reactions to testing HPV positive: implications for the introduction of primary HPV-based cervical screening. Prev Med. 2018;115:90-96.</Citation></Reference><Reference><Citation>Goff SL, Mazor KM, Gagne SJ, Corey KC, Blake DR. Vaccine counseling: a content analysis of patient-physician discussions regarding human papilloma virus vaccine. Vaccine. 2011;29:7343-7349.</Citation></Reference><Reference><Citation>WHO. WHO Director-General Calls for all Countries to Take Action to Help End the Suffering Caused by Cervical Cancer. Geneva, Switzerland: WHO; 2018. https://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/</Citation></Reference><Reference><Citation>Simms KT, Steinberg J, Caruana M, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019;20:394-407.</Citation></Reference><Reference><Citation>Arbyn M, Bruni L, Kelly D, Basu P, Poljak M, Gultekin M. Tackling cervical cancer in Europe amidst the COVID-19 pandemic. Lancet Pub Health. 2020; In Press. https://doi.org/10.1111/1471-0528.16023</Citation></Reference><Reference><Citation>von Karsa L, Arbyn M, De Vuyst H, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavir Res. 2015;1:22-31.</Citation></Reference><Reference><Citation>Ciavattini A, Delli CG, Giannella L, et al. Expert consensus from the Italian Society for Colposcopy and Cervico-Vaginal Pathology (SICPCV) for colposcopy and outpatient surgery of the lower genital tract during the COVID-19 pandemic. Int J Gynaecol Obstet. 2020;149:269-272.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Belgique</li><li>Espagne</li><li>Finlande</li><li>France</li><li>Royaume-Uni</li><li>Slovénie</li><li>Turquie</li></country><region><li>Angleterre</li><li>Auvergne-Rhône-Alpes</li><li>Catalogne</li><li>Grand Londres</li><li>Rhône-Alpes</li><li>Région de Bruxelles-Capitale</li></region><settlement><li>Barcelone</li><li>Bruxelles</li><li>Londres</li><li>Lyon</li><li>Villejuif</li></settlement></list><tree><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Arbyn, Marc" sort="Arbyn, Marc" uniqKey="Arbyn M" first="Marc" last="Arbyn">Marc Arbyn</name></region><name sortKey="Poortmans, Philip" sort="Poortmans, Philip" uniqKey="Poortmans P" first="Philip" last="Poortmans">Philip Poortmans</name><name sortKey="Ritchie, David" sort="Ritchie, David" uniqKey="Ritchie D" first="David" last="Ritchie">David Ritchie</name><name sortKey="Van Den Bruel, Ann" sort="Van Den Bruel, Ann" uniqKey="Van Den Bruel A" first="Ann" last="Van Den Bruel">Ann Van Den Bruel</name></country><country name="Turquie"><noRegion><name sortKey="Gultekin, Murat" sort="Gultekin, Murat" uniqKey="Gultekin M" first="Murat" last="Gultekin">Murat Gultekin</name></noRegion></country><country name="France"><noRegion><name sortKey="Morice, Philippe" sort="Morice, Philippe" uniqKey="Morice P" first="Philippe" last="Morice">Philippe Morice</name></noRegion><name sortKey="Basu, Partha" sort="Basu, Partha" uniqKey="Basu P" first="Partha" last="Basu">Partha Basu</name><name sortKey="Bergeron, Christine" sort="Bergeron, Christine" uniqKey="Bergeron C" first="Christine" last="Bergeron">Christine Bergeron</name><name sortKey="Bray, Freddie" sort="Bray, Freddie" uniqKey="Bray F" first="Freddie" last="Bray">Freddie Bray</name><name sortKey="Weiderpass, Elisabete" sort="Weiderpass, Elisabete" uniqKey="Weiderpass E" first="Elisabete" last="Weiderpass">Elisabete Weiderpass</name></country><country name="Finlande"><noRegion><name sortKey="Nieminen, Pekka" sort="Nieminen, Pekka" uniqKey="Nieminen P" first="Pekka" last="Nieminen">Pekka Nieminen</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Cruickshank, Maggie" sort="Cruickshank, Maggie" uniqKey="Cruickshank M" first="Maggie" last="Cruickshank">Maggie Cruickshank</name></noRegion><name sortKey="Kelly, Daniel" sort="Kelly, Daniel" uniqKey="Kelly D" first="Daniel" last="Kelly">Daniel Kelly</name><name sortKey="Kyrgiou, Maria" sort="Kyrgiou, Maria" uniqKey="Kyrgiou M" first="Maria" last="Kyrgiou">Maria Kyrgiou</name><name sortKey="Kyrgiou, Maria" sort="Kyrgiou, Maria" uniqKey="Kyrgiou M" first="Maria" last="Kyrgiou">Maria Kyrgiou</name></country><country name="Slovénie"><noRegion><name sortKey="Poljak, Mario" sort="Poljak, Mario" uniqKey="Poljak M" first="Mario" last="Poljak">Mario Poljak</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Schmidt, Dietmar" sort="Schmidt, Dietmar" uniqKey="Schmidt D" first="Dietmar" last="Schmidt">Dietmar Schmidt</name></noRegion></country><country name="Espagne"><region name="Catalogne"><name sortKey="Bruni, Laia" sort="Bruni, Laia" uniqKey="Bruni L" first="Laia" last="Bruni">Laia Bruni</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000472 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000472 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32638362
|texte= The European response to the WHO call to eliminate cervical cancer as a public health problem.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32638362" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |